Acceptance of and discontinuation rate from paroxetine treatment in patients with lifelong premature ejaculation

Andrea Salonia, Lorenzo Rocchini, Antonino Sacca', Federico Pellucchi, Matteo Ferrari, Ubaldo Del Carro, Paolo Ribotto, Andrea Gallina, Giuseppe Zanni, Federico Deho', Patrizio Rigatti, Francesco Montorsi

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Introduction: Selective serotonin reuptake inhibitors are the most widely used agents for delaying ejaculation in patients with premature ejaculation (PE). Aim: The aim of this study was to assess the acceptance of and the discontinuation rate from paroxetine treatment in patients with lifelong PE. Methods: We analyzed the acceptance of and discontinuation rates of 93 consecutive potent patients (mean age, 37.6 years) seeking medical treatment for lifelong PE. The patients were assessed with detailed medical and sexual history, self-reported intravaginal ejaculatory latency time, self-administered International Index of Erectile Function, complete physical examination, and the Meares-Stamey test. The patients received a paroxetine prescription (10 mg daily for 21 days and then 20 mg as needed) for the first 3 months. Thereafter, the patients could either stay with the same on-demand treatment or take paroxetine 10 mg daily for 3 months. The patients were evaluated at 3 and 6 months, and requested to complete multiple-choice global assessment questions regarding specific reasons for eventual therapy discontinuation. Main Outcome Measures: The primary end point was acceptance and discontinuation rates for paroxetine treatment in patients seeking medical treatment for lifelong PE. The secondary end point was the reasons for nonacceptance of treatment or discontinuation. Results: Twenty-eight (30.10%) patients decided not to start paroxetine. Fear of using an " antidepressant drug" was the main reason (42.9%) for treatment nonacceptance. Twenty (30.8%) patients who initiated therapy eventually discontinued it. Treatment effect below expectations was the main reason of treatment dropout (75%) during the first 3 months, followed by temporary loss of interest in sex because of relationship issues (15%) and side effects (10%). Of the patients who continued treatment, 77.8% preferred daily paroxetine, while 22.2% continued as-needed therapy. Conclusions: Thirty percent of lifelong PE patients seeking medical treatment for complaints of early ejaculation freely decided not to start any paroxetine treatment, and roughly 30% of patients who started therapy eventually discontinued it.

Original languageEnglish
Pages (from-to)2868-2877
Number of pages10
JournalJournal of Sexual Medicine
Volume6
Issue number10
DOIs
Publication statusPublished - Oct 2009

Fingerprint

Premature Ejaculation
Paroxetine
Therapeutics
Ejaculation

Keywords

  • Acceptance
  • Discontinuation
  • Paroxetine
  • Premature ejaculation
  • Therapy
  • Treatment

ASJC Scopus subject areas

  • Urology
  • Obstetrics and Gynaecology
  • Reproductive Medicine

Cite this

Acceptance of and discontinuation rate from paroxetine treatment in patients with lifelong premature ejaculation. / Salonia, Andrea; Rocchini, Lorenzo; Sacca', Antonino; Pellucchi, Federico; Ferrari, Matteo; Carro, Ubaldo Del; Ribotto, Paolo; Gallina, Andrea; Zanni, Giuseppe; Deho', Federico; Rigatti, Patrizio; Montorsi, Francesco.

In: Journal of Sexual Medicine, Vol. 6, No. 10, 10.2009, p. 2868-2877.

Research output: Contribution to journalArticle

Salonia, A, Rocchini, L, Sacca', A, Pellucchi, F, Ferrari, M, Carro, UD, Ribotto, P, Gallina, A, Zanni, G, Deho', F, Rigatti, P & Montorsi, F 2009, 'Acceptance of and discontinuation rate from paroxetine treatment in patients with lifelong premature ejaculation', Journal of Sexual Medicine, vol. 6, no. 10, pp. 2868-2877. https://doi.org/10.1111/j.1743-6109.2009.01404.x
Salonia, Andrea ; Rocchini, Lorenzo ; Sacca', Antonino ; Pellucchi, Federico ; Ferrari, Matteo ; Carro, Ubaldo Del ; Ribotto, Paolo ; Gallina, Andrea ; Zanni, Giuseppe ; Deho', Federico ; Rigatti, Patrizio ; Montorsi, Francesco. / Acceptance of and discontinuation rate from paroxetine treatment in patients with lifelong premature ejaculation. In: Journal of Sexual Medicine. 2009 ; Vol. 6, No. 10. pp. 2868-2877.
@article{d7790908aa924e588a0031d9a58526a3,
title = "Acceptance of and discontinuation rate from paroxetine treatment in patients with lifelong premature ejaculation",
abstract = "Introduction: Selective serotonin reuptake inhibitors are the most widely used agents for delaying ejaculation in patients with premature ejaculation (PE). Aim: The aim of this study was to assess the acceptance of and the discontinuation rate from paroxetine treatment in patients with lifelong PE. Methods: We analyzed the acceptance of and discontinuation rates of 93 consecutive potent patients (mean age, 37.6 years) seeking medical treatment for lifelong PE. The patients were assessed with detailed medical and sexual history, self-reported intravaginal ejaculatory latency time, self-administered International Index of Erectile Function, complete physical examination, and the Meares-Stamey test. The patients received a paroxetine prescription (10 mg daily for 21 days and then 20 mg as needed) for the first 3 months. Thereafter, the patients could either stay with the same on-demand treatment or take paroxetine 10 mg daily for 3 months. The patients were evaluated at 3 and 6 months, and requested to complete multiple-choice global assessment questions regarding specific reasons for eventual therapy discontinuation. Main Outcome Measures: The primary end point was acceptance and discontinuation rates for paroxetine treatment in patients seeking medical treatment for lifelong PE. The secondary end point was the reasons for nonacceptance of treatment or discontinuation. Results: Twenty-eight (30.10{\%}) patients decided not to start paroxetine. Fear of using an {"} antidepressant drug{"} was the main reason (42.9{\%}) for treatment nonacceptance. Twenty (30.8{\%}) patients who initiated therapy eventually discontinued it. Treatment effect below expectations was the main reason of treatment dropout (75{\%}) during the first 3 months, followed by temporary loss of interest in sex because of relationship issues (15{\%}) and side effects (10{\%}). Of the patients who continued treatment, 77.8{\%} preferred daily paroxetine, while 22.2{\%} continued as-needed therapy. Conclusions: Thirty percent of lifelong PE patients seeking medical treatment for complaints of early ejaculation freely decided not to start any paroxetine treatment, and roughly 30{\%} of patients who started therapy eventually discontinued it.",
keywords = "Acceptance, Discontinuation, Paroxetine, Premature ejaculation, Therapy, Treatment",
author = "Andrea Salonia and Lorenzo Rocchini and Antonino Sacca' and Federico Pellucchi and Matteo Ferrari and Carro, {Ubaldo Del} and Paolo Ribotto and Andrea Gallina and Giuseppe Zanni and Federico Deho' and Patrizio Rigatti and Francesco Montorsi",
year = "2009",
month = "10",
doi = "10.1111/j.1743-6109.2009.01404.x",
language = "English",
volume = "6",
pages = "2868--2877",
journal = "Journal of Sexual Medicine",
issn = "1743-6095",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - Acceptance of and discontinuation rate from paroxetine treatment in patients with lifelong premature ejaculation

AU - Salonia, Andrea

AU - Rocchini, Lorenzo

AU - Sacca', Antonino

AU - Pellucchi, Federico

AU - Ferrari, Matteo

AU - Carro, Ubaldo Del

AU - Ribotto, Paolo

AU - Gallina, Andrea

AU - Zanni, Giuseppe

AU - Deho', Federico

AU - Rigatti, Patrizio

AU - Montorsi, Francesco

PY - 2009/10

Y1 - 2009/10

N2 - Introduction: Selective serotonin reuptake inhibitors are the most widely used agents for delaying ejaculation in patients with premature ejaculation (PE). Aim: The aim of this study was to assess the acceptance of and the discontinuation rate from paroxetine treatment in patients with lifelong PE. Methods: We analyzed the acceptance of and discontinuation rates of 93 consecutive potent patients (mean age, 37.6 years) seeking medical treatment for lifelong PE. The patients were assessed with detailed medical and sexual history, self-reported intravaginal ejaculatory latency time, self-administered International Index of Erectile Function, complete physical examination, and the Meares-Stamey test. The patients received a paroxetine prescription (10 mg daily for 21 days and then 20 mg as needed) for the first 3 months. Thereafter, the patients could either stay with the same on-demand treatment or take paroxetine 10 mg daily for 3 months. The patients were evaluated at 3 and 6 months, and requested to complete multiple-choice global assessment questions regarding specific reasons for eventual therapy discontinuation. Main Outcome Measures: The primary end point was acceptance and discontinuation rates for paroxetine treatment in patients seeking medical treatment for lifelong PE. The secondary end point was the reasons for nonacceptance of treatment or discontinuation. Results: Twenty-eight (30.10%) patients decided not to start paroxetine. Fear of using an " antidepressant drug" was the main reason (42.9%) for treatment nonacceptance. Twenty (30.8%) patients who initiated therapy eventually discontinued it. Treatment effect below expectations was the main reason of treatment dropout (75%) during the first 3 months, followed by temporary loss of interest in sex because of relationship issues (15%) and side effects (10%). Of the patients who continued treatment, 77.8% preferred daily paroxetine, while 22.2% continued as-needed therapy. Conclusions: Thirty percent of lifelong PE patients seeking medical treatment for complaints of early ejaculation freely decided not to start any paroxetine treatment, and roughly 30% of patients who started therapy eventually discontinued it.

AB - Introduction: Selective serotonin reuptake inhibitors are the most widely used agents for delaying ejaculation in patients with premature ejaculation (PE). Aim: The aim of this study was to assess the acceptance of and the discontinuation rate from paroxetine treatment in patients with lifelong PE. Methods: We analyzed the acceptance of and discontinuation rates of 93 consecutive potent patients (mean age, 37.6 years) seeking medical treatment for lifelong PE. The patients were assessed with detailed medical and sexual history, self-reported intravaginal ejaculatory latency time, self-administered International Index of Erectile Function, complete physical examination, and the Meares-Stamey test. The patients received a paroxetine prescription (10 mg daily for 21 days and then 20 mg as needed) for the first 3 months. Thereafter, the patients could either stay with the same on-demand treatment or take paroxetine 10 mg daily for 3 months. The patients were evaluated at 3 and 6 months, and requested to complete multiple-choice global assessment questions regarding specific reasons for eventual therapy discontinuation. Main Outcome Measures: The primary end point was acceptance and discontinuation rates for paroxetine treatment in patients seeking medical treatment for lifelong PE. The secondary end point was the reasons for nonacceptance of treatment or discontinuation. Results: Twenty-eight (30.10%) patients decided not to start paroxetine. Fear of using an " antidepressant drug" was the main reason (42.9%) for treatment nonacceptance. Twenty (30.8%) patients who initiated therapy eventually discontinued it. Treatment effect below expectations was the main reason of treatment dropout (75%) during the first 3 months, followed by temporary loss of interest in sex because of relationship issues (15%) and side effects (10%). Of the patients who continued treatment, 77.8% preferred daily paroxetine, while 22.2% continued as-needed therapy. Conclusions: Thirty percent of lifelong PE patients seeking medical treatment for complaints of early ejaculation freely decided not to start any paroxetine treatment, and roughly 30% of patients who started therapy eventually discontinued it.

KW - Acceptance

KW - Discontinuation

KW - Paroxetine

KW - Premature ejaculation

KW - Therapy

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=70649113739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70649113739&partnerID=8YFLogxK

U2 - 10.1111/j.1743-6109.2009.01404.x

DO - 10.1111/j.1743-6109.2009.01404.x

M3 - Article

C2 - 19656274

AN - SCOPUS:70649113739

VL - 6

SP - 2868

EP - 2877

JO - Journal of Sexual Medicine

JF - Journal of Sexual Medicine

SN - 1743-6095

IS - 10

ER -